Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Landmark clinical results suggest preventative therapy could delay or halt Alzheimer’s onset in high-risk individuals, reshaping the outlook …
Large funding rounds and strategic partnerships highlight a more focused investment environment, concentrating on companies with late stage …
The TROPION-Breast01 phase III study shows that while the ADC datopotamab deruxtecan (Dato-DXd) improves progression-free survival, it does …
Grace Therapeutics reports that its Phase III STRIVE-ON trial showed GTx-104 significantly reduces clinically significant hypotension and improves …
New clinical-stage anti-obesity therapies began breaking ground—designed not just to shed pounds, but to retain muscle, offering a …
Parexel reveals strategic plans to ramp up its Indian operations—underscoring India’s emerging prominence as a critical node in …
Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …
Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
Already a subscriber? Log in